Our recommendations for the Buyback Premium Portfolio center on a collection of five stocks that we believe, as a group, will outperform the market this month.

The Buyback Premium Portfolio has beat the S&P 500 by more than 72% since its inception (August 2, 2000)! It is up 54.87% since inception vs. a decline of 17.90% in the S&P 500. For the month of November, the portfolio gained 3.41% vs. a decline of 0.23% in the S&P 500.

Analyst Upgrades

• BMO Capital upgraded Procter & Gamble (PG) to outperform from market perform as it views P&G's valuation as attractive and expects growth to pick up in the March quarter. The firm has a $74 price target for shares.
• Goldman upgraded Tupperware (TUP) to buy from neutral and raised its target for shares to $60 from $48.
• Stifel Nicolaus upgraded Scansource (SCSC) to buy from hold. The firm believes that the company's growth is poised to accelerate, allowing the stock's multiple to expand or even rise slightly. The firm has a $43 target for shares.
• CA Technologies (CA) was upgraded to outperform from sector perform at RBC Capital.
• Brady (BRC) was upgraded to market perform from underperform at BMO Capital.
• Lukoil (LUKOY) was upgraded to overweight from neutral at JPMorgan.

MOST NOTEWORTHY: Banco Santander, Acorda Therapeutics, Agruim, Annaly Capital and ImmunoGen were today's noteworthy upgrades:

• UBS upgraded shares of Banco Santander (NYSE: STD) to Buy from Neutral as they expect the acquisition of ABN Amro Holding NV (NYSE: ABN) assets in Brazil and Italy to boost earnings in 2008 and 2009.
  
• Friedman Billings added Acorda Therapeutics (NASDAQ: ACOR) to its Top Picks List, as they have confidence in fampridine-SR's safety profile.
  
• Agrium (NYSE: AGU) was upgraded to Sector Outperformer from Sector Performer at CIBC on valuation, as they believe the outlook for wholesale and retail is robust with all three nutrients at historical high levels.
• Annaly Capital Management (NYSE: NLY) was upgraded to Buy from Neutral at UBS, citing likely further FED cuts, benefits from recent secondary, and BVPS growth.
  
• RBC Capital upgraded shares of ImmunoGen (NASDAQ: IMGN) to Outperform from Sector Perform based on valuation, growing pipeline, valuable technology platform, and potential as an acquisition candidate.

OTHER UPGRADES:

• Soleil upgraded ExpressJet Holdings (NYSE: XJT) to Hold from Sell.
  
• Goldman upgraded Assurant (NYSE: AIZ) to Buy from Neutral.
  
• Merill upgraded Forest Labs (NYSE: FRX) to Buy from Neutral.
  
• Citigroup upgraded Domtar (NYSE: UFS) to Buy from Hold.

MOST NOTEWORTHY: Assurant (AIZ), Famous Dave's (DAVE), Trinity Industries (TRN), Spartan Stores (SPTN) and SiRF Technology (SIRF) were today's notable initiations:

• Wachovia believes Assurant (NYSE: AIZ) is a unique opportunity to profit from mortgage market turmoil through its force-placed homeowners business, initiating shares with an Outperform rating.

• Nollenberger initiated Famous Dave's (NASDAQ: DAVE) with a Buy rating and expects to see accelerated earnings growth over the next few years driven by: continued rollout of it's new "Smokehouse" unit format, growth of the off-premise catering and to-go business, and ramp in new development.

• Keybanc is positive on Trinity Industries' (NYSE: TRN) diversified product portfolio, market-leading positions, and long-term end market fundamentals, starting shares with an Aggressive Buy rating.

• Banc of America initiated Spartan Stores (NASDAQ: SPTN) with a Buy and believes the company should benefit from the roll-up of independent retail assets and the move toward a customer-centric operating model.

• Banc of America believes rising competitive pressures in PNDs will lead to significant market share erosion in 2008 and started SiRF Technology (NASDAQ: SIRF) with a Neutral rating...

OTHER INTIATIONS:

• Wachovia initiated Dice Holdings (NYSE: DHX) with an Outperform rating.

• Stifel initiated Bancshares of Florida (NASDAQ: BOFL) and TIB Financial (NASDAQ: TIBB) with Hold ratings.

• Nollenberger initiated Morton's Restaurant (NYSE: MRT) with a Buy rating.

• Ceradyne (NASDAQ: CRDN) was initiated with a Hold rating at Morgan Joseph.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).